Skip to content
To the full analysis

Intco Medical Technology Stock: Key Metrics

300677.SZ
$7.23Closing price of 20 Nov 2026MEQIRI Score 45 out of 100

Intco Medical Technology had an operating margin of 12.4% and a return on invested capital (ROIC) of 6% in fiscal 2025.

Margins show how much of revenue is left over, returns on capital how hard the invested money works.

Daily figure as of 20 Nov 2026

Margins

  • Gross margin
  • Operating margin
  • Net margin
Figures as a table
YearGross marginOperating marginNet margin
201314.9%3.9%1.5%
201417.8%4.5%3.6%
201526.4%7.9%6.4%
201624.5%8.5%7.3%
201724.8%9.6%8.3%
201824.7%10.8%9.5%
201925.0%9.7%8.6%
202069.0%60.5%50.6%
202161.4%53.5%45.8%
202212.7%10.7%9.5%
202313.6%6.3%5.5%
202422.8%17.6%15.4%
202524.1%12.4%10.2%

Returns on Capital

  • ROE
  • ROIC
  • ROA
Figures as a table
YearROEROICROA
20137.3%8.9%1.5%
201418.9%10.2%4.9%
201515.5%15.8%8.5%
201616.1%13.6%7.4%
201713.3%16.5%8.7%
201814.1%15.7%7.4%
201912.1%12.4%6.0%
202075.0%284.8%54.2%
202146.8%131.5%36.0%
20224.0%6.7%2.9%
20232.4%3.5%1.4%
20248.4%13.7%4.2%
20255.5%6.0%2.5%
Buyback calculator for Intco Medical Technology

Data and Required Disclosures

  • ; time horizon around 12 months
  • Rated Weak since 7 Nov 2026; valuation signal Fairly valued since 20 Nov 2026
  • Price: closing price of 20 Nov 2026
  • Amounts in US dollars at the ECB reference rate of 19 Nov 2026 ($1 = CN¥6.6667)
  • Data from Financial Modeling Prep (FMP) based on the company's reports, latest fiscal year 2025. MEQIRI calculates the score and fair value itself every night.
  • Score and fair value are estimates from a disclosed model. They are not facts and not a price target.
  • Produced by SSM Ventures UG (haftungsbeschränkt), responsible person Sven Brostmeyer, Managing Director, automatically according to the disclosed model.
  • Not investment advice. Losses up to and including a total loss are possible. Personal circumstances are not considered.